Business Wire

Excellence in Product Development Shapes Beverage Innovations in Europe, According to NielsenIQ BASES Annual Breakthrough Innovations Report

9.11.2021 09:01:00 EET | Business Wire | Press release

Share

As beverage innovations sweep up the most accolades across Europe in NielsenIQ BASES Breakthrough Innovation Report, released today, the findings highlight a number of leading trends that drinks manufacturers should be prepared to tap into in 2022 and beyond.

The report, which celebrates its 10th anniversary this year, has unveiled the leading innovations of the FMCG world that have made the biggest impact. The brands that made the list reflect a wide range of products and approaches that succeeded in making meaningful connections with consumers, an impressive feat within an increasingly crowded marketplace. With beverage launches accounting for over a third of Europe’s leading FMCG innovations, the winners highlight a further shift towards premiumisation in the drinks industry.

Leffe d'Été in France and Hansa Mango IPA in Norway achieved sales success by attracting new consumers into the brand and category, overcoming taste barriers associated with lager and IPA respectively.

Hansa Mango IPA, has been hugely successful in Norway after focusing on creating a beverage that is easy to drink by toning down on the natural bitter beer taste, particularly pertinent for IPA. Following extensive consumer testing, the team found that mango paired well with hopped IPA/beer and even improved the texture. Hansa Mango IPA also leveraged its retailer connections to secure strong listings with good visibility for the launch - critical in a country and category where advertising is banned. Initially intended as a limited summer edition, it is now a permanent product.

The launch of Martini Fiero offered consumers a new flavour profile and an easy to execute perfect serve to drive growth in the declining vermouth category, which was losing relevancy in Russia as consumers moved into modern aperitivo occasion. Bacardi identified an opportunity for Martini Fiero, a drink that is 100% natural in flavour and colour with a bittersweet, orange taste, to bring the vermouth category into this new occasion.

Shifting focus to the growing coffee market, Costa Coffee UK saw an opportunity to bring their out of home brand into consumers’ homes through entering the Ready-to-Drink category. The category was small but growing fast; Costa identified an opportunity to combine its coffee credentials and expertise to create a winning cold coffee proposition. The result was an RTD with authentic coffee flavour and less sugar than other products in the category.

Celine Grena, European BASES leader, comments: “Looking at this year’s winners, we can see a huge number of beverages leading the way for FMCG innovations. Taste remains one of the most important factors within the drinks category, with focus on the product development process playing a key role for the winners. It’s also worth noting that this strategy allows manufacturers to justify a premium, with nearly two-thirds of beverage winners premium to the category.”

Beverage Winners (listed in alphabetical order)

  • Birra Messina Cristalli Di Sale (Italy)
  • Costa Coffee Ready-to-Drink (UK)
  • Hansa Mango IPA (Norway)
  • Innocent Plus (UK & France)
  • J.J Whitley – Artisanal Russian Vodka (UK)
  • Leffe d'Été (France)
  • Martini Fiero (Russia)
  • Somersby Mango i Limonka (Poland)
  • Starbucks for Nespresso (UK, France, Switzerland, Netherlands and Spain)

About NielsenIQ BASES Breakthrough Innovation

This year’s Breakthrough Innovation process reviewed over 50,000 product launches. The brands that made the 2021 list reflect a wide range of products and approaches that succeeded in making meaningful connections with consumers, an impressive feat within an increasingly crowded marketplace. Beyond BASES requirements for products that reflect strong, distinct qualities such as mass potential, longevity, brand incrementality, category distinction or appeal toward a specific consumer target, this year’s list brings the continued evolution of the success criteria, which includes all six of NielsenIQ BASES’ activation profiles.

About NielsenIQ

NielsenIQ is the leader in providing the most complete, unbiased view of consumer behavior, globally. Powered by a groundbreaking consumer data platform and fueled by rich analytic capabilities, NielsenIQ enables bold, confident decision-making for the world’s leading consumer goods companies and retailers.

Using comprehensive data sets and measuring all transactions equally, NielsenIQ gives clients a forward-looking view into consumer behavior in order to optimize performance across all retail platforms. Our open philosophy on data integration enables the most influential consumer data sets on the planet. NielsenIQ delivers the complete truth.

NielsenIQ, an Advent International portfolio company, has operations in nearly 100 markets, covering more than 90% of the world’s population. For more information, visit NielsenIQ.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Publicasity
Gillian Mosher
NielsenIQ@publicasity.co.uk

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye